Long-term (52–78 weeks) treatment with colesevelam HCl added to metformin therapy in type 2 diabetes mellitus patients
Harold E BaysLouisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, USAObjective: To evaluate the long-term safety, tolerability, and efficacy of colesevelam HCl (colesevelam) in type 2 diabetes mellitus patients receiving metformin monotherapy or metformin combination thera...
Saved in:
Main Author: | Bays HE |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2012
|
Subjects: | |
Online Access: | https://doaj.org/article/e3d6a34ccecb4e2cbc0af2f58703c244 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam – a clinical perspective
by: Ronald B Goldberg
Published: (2009) -
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Karen Barnard, et al.
Published: (2010) -
Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
by: Holl, et al.
Published: (2014) -
Fixed-dose combinations in type 2 diabetes – role of the canagliflozin metformin combination
by: Fleming JW, et al.
Published: (2015) -
Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated
by: Irons BK, et al.
Published: (2014)